COA5-Related Fatal Infantile Cardioencephalomyopathy

1. Disease Information

Overview. An autosomal recessive, neonatal/early-infantile mitochondrial disorder caused by biallelic loss-of-function variants in COA5 (Cytochrome c Oxidase Assembly Factor 5, formerly C2orf64), which encodes a small CHCH-domain protein required for an early step of respiratory chain Complex IV (cytochrome c oxidase, COX) assembly. Disease is defined by isolated Complex IV deficiency producing rapidly fatal hypertrophic cardiomyopathy with lactic acidosis in the neonatal period; the "cardioencephalomyopathy" nosology reflects the broader OMIM disease-class naming convention for this group of nuclear COX-assembly disorders rather than a documented, prominent primary CNS lesion in the reported cases (see §3, §7).

Key identifiers: - OMIM gene: 613920 — COA5 (Huigsloot et al. 2011) - OMIM phenotype: #616500 — Mitochondrial Complex IV Deficiency, Nuclear Type 9 (MC4DN9); also referenced in the literature as CEMCOX3 (Cardioencephalomyopathy, Fatal Infantile, due to Cytochrome c Oxidase Deficiency 3) (omim.org/entry/616500) - MONDO: MONDO:0014667 (corresponds to MC4DN9) - Gene location: 2q11.2; NCBI Gene ID 493753; RefSeq NM_001008215.3; also historically NCOA5-adjacent nomenclature confusion should be avoided — COA5 ≠ NCOA5 (nuclear receptor coactivator 5), a distinct, unrelated gene that surfaces in naive searches - Orphanet: ORPHA:1561 — Fatal infantile cytochrome C oxidase deficiency (the broader COX-deficiency umbrella term Orphanet uses; COA5 is one of several causal genes grouped here) (orpha.net/en/disease/detail/1561) - Yeast ortholog: PET191

Synonyms: Cytochrome c oxidase assembly factor 5 deficiency; C2ORF64-related mitochondrial disease; MC4DN9; CEMCOX3.

Evidence base. This is an extremely narrowly-documented Mendelian entity: the primary clinical source is a single index report of one consanguineous Turkish family (2 affected sibs) (Huigsloot et al. 2011, PMID:21457908), corroborated by one additional, unrelated family carrying the identical variant, reported in a 2024–2025 mechanistic follow-up (Stroud lab / Life Science Alliance, PMID:39779219). All published human genotype-phenotype data currently trace to these two families and the single recurrent variant p.Ala53Pro — this is aggregated disease-level literature (case reports), not an EHR/registry-derived dataset.

Sources: OMIM #616500 · OMIM *613920 · Orphanet ORPHA:1561 · NCBI Gene 493753

2. Etiology

Disease causal factor: Purely monogenic/genetic — biallelic (homozygous, in both reported families) pathogenic variants in COA5 (hgnc gene; lowercase-hgnc: CURIE per local convention would be hgnc:24704, ENSG00000183513). No environmental, infectious, or multifactorial contribution has been reported or is biologically plausible for this class of nuclear mitochondrial assembly-factor disorder.

Genetic risk factor / founder variant: The only variant reported in humans to date is c.157G>C (p.Ala53Pro, NM_001008215.3), identified in homozygosity in both unrelated reported families, both of Turkish ethnicity — strongly suggestive of a Turkish founder allele, though a formal haplotype/founder-effect study has not been published (this is an inference from the recurrence pattern, not an established finding). PMID:21457908 originally identified the variant in a consanguineous Turkish pedigree; the second, independently ascertained Turkish family carrying the same allele was reported in the 2024/2025 functional-mechanism paper (PMID:39779219), which itself functions as a form of independent case confirmation.

• Population allele frequency: gnomAD frequency data specific to c.157G>C were not retrieved in this search pass; given its apparent restriction to Turkish founder chromosomes and the ultra-rare disease phenotype, expect it to be present at very low frequency or absent from gnomAD's predominantly non-Turkish-enriched reference panels — this should be confirmed directly in gnomAD before KB entry, as it was not independently verified here.
• No modifier genes, susceptibility loci, or protective variants have been reported for this disorder — there is no literature to draw on for §2's "Protective Factors" or "Gene-Environment Interactions" subsections; state this as a genuine gap rather than inferring an absence.

Consanguinity: Explicitly documented in the index family ("consanguineous Turkish parents," PMID:21457908), consistent with autosomal recessive transmission of a rare founder allele.

Sources: OMIM *613920 · Huigsloot et al. 2011, PMID:21457908 · PMC11711468/PMID:39779219

3. Phenotypes

Phenotype data derive entirely from the two reported Turkish families (Huigsloot 2011 index sibs, died at 8 and 10 days of age per the OMIM/NORD abstraction, though one search summary reported "3 months" — this discrepancy should be resolved against the primary PMID:21457908 full text before curation, since GARD/OMIM abstractions and AI-search summaries of the same paper conflicted on exact age at death).

Severity/progression: Uniformly severe and rapidly fatal in both reported families; no surviving patients, no reported milder allelic series, and therefore no data exist on variable severity, later-onset presentations, or long-term natural history — unlike many other MC4DN subtypes (e.g., SURF1-Leigh syndrome), which have a phenotypic spectrum, COA5-disease as currently documented is a single, severe, lethal-in-infancy phenotype defined by n=2 families.

CNS/encephalopathy phenotype specifically: The disease-class name ("cardioencephalomyopathy") implies CNS involvement, but the retrieved abstracts and summaries emphasize the cardiac and biochemical phenotype far more than a distinct, well-characterized encephalopathic phenotype (e.g., no MRI/neuroimaging findings, no seizure phenotype, and no dedicated neurological exam findings were surfaced in this search). This is a gap that should be resolved by reading the PMID:21457908 full text directly — the CNS component of the phenotype may be present in the primary paper but was not captured by the search summaries used here, or the "cardioencephalomyopathy" label may be inherited from the broader disease-class nomenclature (OMIM's naming convention for this class of COX-deficiency disorders) rather than from a specific encephalopathy documented in these two families. Flag this explicitly rather than asserting a CNS phenotype without primary-source confirmation.

Quality of life impact: Not applicable/not reported — given uniform neonatal/early-infantile lethality, no QOL instrument data (EQ-5D, SF-36) exist or would be expected.

Sources: PMID:21457908 (Huigsloot et al. 2011, Am J Hum Genet 88:488–493) · NORD/MONDO abstraction · GTR test record · PMID:39779219

4. Genetic/Molecular Information

Causal gene: COA5 (OMIM 613920; NCBI Gene 493753; chr2q11.2; NM_001008215.3). Historical alias: C2orf64*.

Reported pathogenic variant: - c.157G>C, p.(Ala53Pro) — the sole variant reported in humans across both families. - Variant type: Missense, homozygous (biallelic) in both reported pedigrees. - ACMG classification: Not independently retrieved from ClinVar in this pass — should be pulled directly from ClinVar before KB curation, but functional data (below) strongly support a damaging/loss-of-function-type mechanism. - Location: Falls within a conserved motif of the COA5/PET191 protein predicted to be important for protein folding/structure (per PMID:21457908's original functional characterization). - Population frequency: Not independently confirmed here (see §2) — recommend a direct gnomAD/ClinVar pull. - Origin: Germline (both reported cases), consistent with autosomal recessive constitutional disease; not a somatic/cancer-associated gene.

Protein and functional consequence: - COA5 is a small mitochondrial intermembrane-space protein containing a CHCH domain with twin CX9C motifs — a structural class that depends on the MIA40/CHCHD4 disulfide-relay import pathway for mitochondrial localization (general class-level inference; not explicitly confirmed for COA5 in the sources retrieved here, so should be flagged as inferred-from-domain-architecture rather than COA5-specific experimental confirmation). - Ortholog of yeast Pet191, a subunit of an oligomeric inner-membrane-associated complex required for COX assembly; early yeast Pet191 studies suggested a role in COX assembly without direct impact on mitochondrial translation or copper metalation of COX subunits. - Functional impact category: Best characterized as loss-of-function / partial loss-of-function — p.Ala53Pro patient fibroblasts show: - Isolated Complex IV enzymatic deficiency (both fibroblasts and patient heart muscle) - Accumulation of Complex IV assembly intermediates/subcomplexes rather than mature holocomplex - Subcomplexes lacking COX1 (MT-CO1), COX2 (MT-CO2), COX4 (COX4I1), and COX5A subunits (PMID:21457908) - The 2024/2025 mechanistic paper (PMID:39779219) refined this: complexome profiling in a CRISPR/Cas9 COA5-knockout U2OS cell line (7-bp frameshift deletion) showed COA5 acts specifically between MT-CO1 maturation and the incorporation of MT-CO2 into the earliest CIV assembly intermediate — i.e., COA5 loss blocks a discrete, early step, with accumulation of MT-CO1-containing subcomplexes (100–300 kDa) that cannot progress to a functional holocomplex. - No modifier genes have been reported. - No epigenetic data (methylation, histone modification) have been reported for this gene/disease — genuine gap, not to be inferred. - No chromosomal-abnormality (CNV, translocation, aneuploidy) mechanism has been reported; disease is driven by a point missense variant only.

Suggested ontology bindings: hgnc gene term for COA5 (verify exact HGNC ID before binding — do not guess the numeric CURIE without an OAK/HGNC lookup); GO:0033617 (mitochondrial respiratory chain complex IV assembly) as the key biological-process term; molecular function terms around CHCH-domain/protein-folding chaperone activity should be verified against UniProt/GO rather than asserted from this search pass.

Sources: PMID:21457908 · PMID:39779219 (PMC11711468) · OMIM *613920 · NCBI Gene 493753

5. Environmental Information

No environmental, lifestyle, or infectious causal/risk factors have been reported for this disorder, consistent with its status as a fully penetrant, biallelic monogenic mitochondrial assembly-factor disease presenting at birth/neonatally. This is a genuine "not applicable" rather than an unresearched gap — nuclear-encoded COX-assembly-factor disorders of this class are not known to have environmental modifiers of onset or severity in the pediatric mitochondrial disease literature generally, though a disease-specific search for gene-environment interaction data specific to COA5 returned nothing to cite.

6. Mechanism / Pathophysiology

Causal chain (numbered, from molecular lesion to clinical phenotype):

1. Biallelic COA5 c.157G>C (p.Ala53Pro) variant → destabilizes a conserved motif of the COA5/PET191-family CHCH-domain protein, impairing its folding/structural integrity (PMID:21457908; mechanism of destabilization is inferred from conservation and structural prediction in the original paper, not from a solved crystal structure).
2. Loss of functional COA5 protein → arrest of Complex IV (cytochrome c oxidase) assembly at an early, discrete step — specifically between maturation of the mitochondrially-encoded COX1 (MT-CO1) subunit and its combination with COX2 (MT-CO2) to form the earliest CIV assembly intermediate (PMID:39779219, complexome profiling in the COA5-knockout cellular model). This step is directly demonstrated in the CRISPR-knockout cell system; its equivalence to the patient p.A53P mechanism is supported by concordant biochemical findings in patient fibroblasts (accumulating the same class of subcomplexes) but the knockout and missense mechanisms are not proven identical at the structural level — this is a reasonable inference, not a demonstrated one-to-one mechanistic match.
3. Failure to progress past this intermediate → accumulation of stalled MT-CO1-containing subcomplexes (~100–300 kDa) that cannot mature into the CIV holocomplex; these appear to be routed toward a prohibitin-complex-associated pathway, consistent with a degradative/quality-control fate for unassembled respiratory-chain subunits (PMID:39779219 — described as "colocalisation with prohibitin complexes," suggestive of degradation but not directly proven to be degradation via a specific proteolytic mechanism in the retrieved summary).
4. Net loss of mature Complex IV holocomplex → markedly reduced Complex IV enzymatic activity and abundance, while Complexes I, II, III, and V remain relatively unaffected (isolated CIV deficiency) — directly demonstrated in both patient fibroblasts/heart muscle (PMID:21457908) and the knockout cell model (PMID:39779219).
5. Loss of CIV activity → secondary loss of respiratory supercomplex assembly, specifically loss of the III₂+IV supercomplex and a compensatory increase in the CI+III₂ "S0" supercomplex (PMID:39779219) — this represents a downstream structural reorganization of the respiratory chain rather than a separate causal branch.
6. Combined loss of CIV activity and supercomplex disruption → impaired oxidative phosphorylation capacity, particularly in high-energy-demand tissues (cardiac and skeletal muscle, and — per the disease-class "cardioencephalomyopathy" designation — potentially CNS, though the CNS mechanistic link is not directly documented in the sources retrieved here; flag as an assumed-by-nosology rather than demonstrated link) → compensatory anaerobic glycolysis, producing the observed lactic acidosis (elevated blood and urinary lactate) and elevated urinary ethylmalonic acid (a marker of disrupted mitochondrial fatty-acid/energy metabolism).
7. Chronic energy failure in cardiomyocytes → hypertrophic cardiomyopathy with septal hypertrophy and non-compaction features, the dominant clinical phenotype in both reported families.
8. Combined cardiac pump failure, respiratory insufficiency (from concurrent skeletal/respiratory muscle energy failure and possible CNS respiratory drive involvement — again, the CNS component is asserted by disease-class nomenclature more than by a directly cited mechanistic finding in this search pass), and multisystem metabolic decompensation → death in early infancy.

Molecular pathway: Mitochondrial respiratory chain Complex IV (cytochrome c oxidase) biogenesis pathway; GO:0033617 (mitochondrial respiratory chain complex IV assembly) is the key suggested GO term. No involvement of canonical signaling cascades (Wnt/MAPK/mTOR/PI3K-AKT) — this is a structural/metabolic assembly-factor disorder, not a signaling disorder.

Cellular process: Impaired oxidative phosphorylation; compensatory glycolytic shift; likely proteostatic/degradative handling of stalled assembly intermediates via prohibitin-associated pathways (PMID:39779219).

Protein dysfunction: Loss-of-function/misfolding of a small CHCH-domain chaperone-like assembly factor (COA5), leading to failure of a specific protein-protein assembly step (MT-CO1 + MT-CO2 incorporation) rather than a defect in COX catalytic chemistry itself.

Tissue damage mechanism: Energy-failure-driven cardiomyocyte dysfunction/hypertrophy; no evidence retrieved here for oxidative-stress, fibrotic, or necrotic mechanisms specifically documented in COA5 disease (though these are plausible extrapolations from mitochondrial cardiomyopathy biology generally — do not assert them as COA5-specific findings).

Cell types/anatomical involvement (see also §7): Cardiomyocytes (primary, best-documented); skeletal muscle/fibroblasts (biochemically characterized, PMID:21457908); U2OS (human osteosarcoma) cell line used as the mechanistic knockout model (PMID:39779219) — note this is an experimental/heterologous cell model, not a disease-relevant tissue, and should be labeled accordingly in any experimental_models entry.

Omics/advanced technologies: Complexome profiling (a specialized proteomic/native-PAGE-based technique resolving native protein complex composition across a molecular-weight gradient) was the key advanced technology used in PMID:39779219 to map the precise assembly stage at which COA5 acts. No transcriptomic (RNA-seq/GEO), standard proteomic (PRIDE), metabolomic, lipidomic, single-cell, or spatial transcriptomic datasets specific to COA5 disease were identified in this search — a genuine gap, not to be inferred as absent from all databases without a direct GEO/PRIDE query.

Suggested GO terms: GO:0033617 (mitochondrial respiratory chain complex IV assembly). Suggested CL terms: CL:0000746 (cardiac muscle cell) for the primary affected cell type; CL:0000057 (fibroblast) for the biochemically characterized cell type.

Sources: PMID:21457908 · PMID:39779219 (Life Science Alliance / PMC11711468)

7. Anatomical Structures Affected

Organ level: - Primary: Heart (hypertrophic cardiomyopathy — the dominant, best-documented organ manifestation in both families) - Secondary/systemic: Liver (abnormal LFTs reported); respiratory system (respiratory insufficiency, though this may be secondary to cardiac failure and/or generalized hypotonia/muscle weakness rather than a distinct primary respiratory-organ lesion) - Body systems: Cardiovascular (primary); metabolic/endocrine (lactic acidosis, organic aciduria); neuromuscular (hypotonia); the "encephalo-" component of the disease-class name implies CNS involvement, but a specific CNS lesion (imaging finding, defined encephalopathy phenotype) was not identified in the sources retrieved in this pass and should be confirmed from the PMID:21457908 full text before being curated as a distinct phenotype/organ node.

Tissue and cell level: Cardiac muscle tissue (myocardium — septal hypertrophy, non-compaction pattern) is the most specifically documented; skeletal muscle biopsy tissue was studied in at least the second reported family (per the 2024/2025 paper's mention of "skeletal muscle biopsies"); dermal fibroblasts were the primary cultured cell type used for biochemical/functional characterization in both the original and follow-up studies.

Subcellular level: Mitochondrial inner membrane / intermembrane space — COA5 is an intermembrane-space CHCH-domain protein associated with the assembly machinery on the matrix side of the inner membrane where nascent Complex IV subcomplexes form. Suggested GO Cellular Component term: GO:0005758 (mitochondrial intermembrane space) — verify against UniProt subcellular-location annotation before binding, as the exact sub-compartment (inner membrane vs. IMS-soluble vs. IMS-membrane-associated) was not confirmed to UniProt-level precision in this search pass.

Localization/laterality: Not applicable — this is a systemic/biventricular process (biventricular hypertrophic cardiomyopathy reported), not a lateralized or focal anatomical process.

Suggested UBERON terms: UBERON:0000948 (heart); UBERON:0002349 (myocardium); UBERON:0001133 (cardiac ventricle) for biventricular involvement — verify specificity against the primary source before binding.

8. Temporal Development

• Onset: Congenital/neonatal — both reported families presented at birth or within the first days of life (hypotonia and respiratory insufficiency at birth per one abstraction; cardiomyopathy identified in the neonatal period in both families).
• Onset pattern: Acute-to-subacute, rapidly progressive.
• Disease course: Uniformly progressive to death — no stable, relapsing-remitting, or spontaneously-improving course has been documented. This is a monophasic, rapidly fatal natural history as currently reported.
• Duration/outcome: Death reported at 8 and 10 days of age in the index sibs per the OMIM/NORD-derived abstraction; one search-tool summary of the same paper stated "fatal outcome at 3 months of age" — this is a direct conflict in secondary sources that must be resolved against the PMID:21457908 primary text before any age-at-death value is entered into the KB. Do not average or guess between these two conflicting figures.
• Stages: No formal staging system exists for this ultra-rare, uniformly fatal infantile disorder.
• Critical periods: The entire disease course occurs within a critical early-infantile window; no data exist on any therapeutic window or intervention timing given the absence of reported surviving/treated patients.

9. Inheritance and Population

• Inheritance pattern: Autosomal recessive (biallelic), confirmed in both reported families, including documented parental consanguinity in the index pedigree.
• Penetrance: Appears fully penetrant in the (very small, n=2-family) reported cohort — both affected sibs in the index family were symptomatic and died; no asymptomatic or mildly-affected biallelic carriers have been reported. Given the extremely small sample size, a formal penetrance estimate cannot be responsibly asserted beyond "apparently complete in the cases reported."
• Expressivity: Cannot be meaningfully assessed — only a single recurrent variant (p.Ala53Pro) has been reported in humans, in two families with a grossly concordant, severe, lethal phenotype; there is no allelic series to demonstrate variable expressivity.
• Genetic anticipation, germline mosaicism: Not applicable/not reported — no repeat-expansion mechanism, and no mosaicism data reported.
• Founder effect: Strongly suspected (see §2) — both reported unrelated families are Turkish, and the identical c.157G>C variant was found in both, but a formal founder-haplotype study has not been published in the sources retrieved here.
• Carrier frequency: Not established/not reported.
• Epidemiology (prevalence/incidence): No formal prevalence or incidence estimate exists. This is one of the rarest entries in the MC4DN (mitochondrial Complex IV deficiency, nuclear type) disease group, with only two published families worldwide. Orphanet's ORPHA:1561 entry covers the broader "fatal infantile cytochrome C oxidase deficiency" umbrella (multiple causal genes), not a COA5-specific prevalence figure — do not conflate the umbrella-term prevalence with a COA5-specific number, as none exists.
• Population demographics: Both reported families of Turkish ethnicity; no data on prevalence or geographic distribution beyond this. Sex ratio: not distinctively reported (mitochondrial nuclear-gene AR disorders generally show no sex bias, consistent with autosomal — not X-linked or mitochondrial-DNA — transmission here).

10. Diagnostics

Laboratory tests: - Blood lactate (elevated, 2.5–11 mmol/L reported range) - Urinary lactate and ethylmalonic acid (elevated) - Liver function tests (abnormal) - Muscle/fibroblast Complex IV (cytochrome c oxidase) enzymatic activity assay — the key confirmatory biochemical test, showing isolated, severe CIV deficiency with normal activity of Complexes I, II, III, V

Imaging: Echocardiography — demonstrated biventricular hypertrophic cardiomyopathy with septal hypertrophy and a non-compaction myocardial appearance in the reported cases; no further imaging modality detail (cardiac MRI, brain MRI) was retrieved in this search pass.

Genetic testing: Clinically available as a targeted sequence-analysis test for all coding COA5 exons (postnatal), listed in NCBI's Genetic Testing Registry under the CEMCOX3/MC4DN9 indication (GTR test 586086); would also be captured on any mitochondrial Complex IV deficiency gene panel and on exome/genome sequencing given the nonspecific, phenotypically-overlapping presentation shared across the MC4DN gene group (COA5, COA6, COA7, SURF1, SCO1/2, COX10/15, PET100, NDUFA4, etc.).

Confirmatory functional/research-level testing: Complexome profiling and immunoblotting for COX assembly intermediates (as performed in PMID:39779219) — this is a research-level rather than routine clinical diagnostic tool at present.

Differential diagnosis: Other nuclear-encoded Complex IV assembly-factor disorders presenting with neonatal hypertrophic cardiomyopathy and lactic acidosis — notably SCO2-related fatal infantile cardioencephalomyopathy (a classic, better-characterized member of this disease class and likely the original prototype for the "cardioencephalomyopathy" naming convention), COX15, COA6, and other MC4DN subtypes; also mitochondrial DNA-encoded COX-subunit defects and other primary mitochondrial cardiomyopathies (e.g., MTO1, TAZ/Barth syndrome, and other respiratory-chain-complex disorders) should be considered and excluded biochemically/genetically.

Screening: No population or newborn-screening program specifically targets COA5-related disease; given its rarity this would not be expected to appear on standard newborn metabolic screening panels (which target treatable inborn errors of metabolism, and this disorder currently has no disease-modifying treatment — see §12).

11. Outcome/Prognosis

• Survival/mortality: Uniformly fatal in early infancy in all reported cases (8–10 days per one source; "3 months" per a conflicting secondary summary — resolve against primary text, see §8). No long-term survivors have been reported in the literature retrieved here.
• Life expectancy: Days to at most a few months, based on the two reported families; this is among the most rapidly fatal entries in the mitochondrial Complex IV deficiency disease group as currently documented.
• Morbidity/complications: Respiratory insufficiency requiring intubation, hepatic dysfunction, and progressive cardiac failure were the reported proximate complications leading to death.
• Recovery potential: None reported/expected given the uniformly fatal course and absence of any reported disease-modifying intervention.
• Prognostic factors/biomarkers: No prognostic stratification exists — the extremely small reported cohort (n=2 families) with concordant severe outcomes precludes any meaningful biomarker-based prognostic modeling at this time.

12. Treatment

No disease-specific, disease-modifying, or FDA-approved treatment exists for COA5-related disease. No pharmacotherapy, gene therapy, cell therapy, or targeted molecular therapy trial was identified for this specific gene/disease in this search pass, and none would be expected given its ultra-rarity (two published families) and the absence of any registered clinical trial.

What can be stated, by extrapolation from general mitochondrial disease management (and should be clearly labeled in any KB entry as general supportive-care extrapolation, not COA5-specific evidence): - Supportive care for hypertrophic cardiomyopathy and respiratory insufficiency (e.g., NCIT:C15747 Supportive Care; NCIT:C15986 Pharmacotherapy for symptomatic cardiac management such as diuretics/beta-blockers, though no COA5-specific citation supports their use) - Standard "mitochondrial cocktail" supplementation (CoQ10, riboflavin, carnitine, thiamine) is commonly used empirically across the broader mitochondrial respiratory chain disease group, but no COA5-specific evidence of efficacy was found in this search — do not curate this as evidence-supported for this specific gene without a direct citation. - No gene therapy, RNA-based therapy, or targeted precision-medicine approach has been reported or is in development specifically for COA5 disease.

Clinical trials: No registered ClinicalTrials.gov entry specific to COA5-related disease was identified in this search pass.

This is a genuine and clinically important gap to flag explicitly in the KB entry: treatment content for this disorder should be limited to general supportive-care framing, clearly distinguished from disease-specific evidence, consistent with the two-family, no-survivor natural history described above.

13. Prevention

• Primary prevention: Genetic counseling for consanguineous families/carrier couples, particularly relevant given the documented consanguinity in the index family and the apparent Turkish founder-variant pattern (see §2, §9). Suggested NCIT term: NCIT:C15240 (Genetic Counseling).
• Secondary prevention/screening: Carrier screening and prenatal/preimplantation genetic testing are reasonable extrapolated recommendations for families with a known COA5 pathogenic variant (standard practice for any severe, early-lethal autosomal recessive disorder with an identified causal variant), but no COA5-specific carrier-screening program, prenatal-testing case report, or PGD case has been published in the sources retrieved here — this should be flagged as inferred-by-analogy rather than directly evidenced.
• Tertiary prevention: Not applicable given the absence of any reported surviving/treated patients in whom complication-prevention strategies could be documented.
• No population-level, public-health, immunization, or environmental-intervention prevention strategy is applicable to this purely monogenic disorder.

14. Other Species / Natural Disease

No naturally-occurring COA5-related disease has been reported in any non-human species (companion animal, livestock, or wildlife) in the sources retrieved here — a search of veterinary/OMIA-type sources specific to COA5 did not surface any hits, and this should be treated as a genuine absence rather than an unresearched gap, consistent with COA5 disease being an ultra-rare human founder-variant condition rather than a naturally recurring animal phenotype.

Orthology: COA5 is conserved from yeast (Pet191) through mouse (Coa5, MGI:1923428) to human, consistent with its fundamental, evolutionarily conserved role in Complex IV biogenesis (see §15 for mouse-specific data).

15. Model Organisms

• Yeast (Saccharomyces cerevisiae): PET191 — the original ortholog studied; early yeast work established a role in COX assembly without a demonstrated direct effect on mitochondrial translation or copper metalation of COX subunits (per the mechanistic background cited in PMID:39779219's discussion). This represents indirect/orthology-based model support rather than a disease-recapitulating model.
• Mouse: Coa5 (MGI:1923428) has multiple targeted, gene-trapped, and chemically-induced alleles catalogued (9 total alleles; 7 strains available via IMSR), with phenotype annotations spanning behavioral/neurological, embryonic development, endocrine, growth, integument, mortality/aging, and reproductive categories per the MGI summary retrieved. However, the specific phenotypic details, zygosity (heterozygous vs. homozygous), and whether homozygous null is embryonic lethal were not resolved in this search pass — this is an important gap: if Coa5-null mice are embryonic lethal, that would be a directly relevant "does the null model recapitulate/exceed the human phenotype" finding (bearing on human-model-fidelity assessment) and should be pulled from MGI's detailed phenotype allele pages before KB curation, rather than asserted here without direct confirmation.
• Human cellular model (heterologous): CRISPR/Cas9-engineered COA5-knockout U2OS (human osteosarcoma) cell line (7-bp frameshift deletion) — this is the best-characterized functional model, directly recapitulating isolated Complex IV enzymatic deficiency and the same class of stalled MT-CO1-containing assembly subcomplexes seen in patient fibroblasts (PMID:39779219). Because U2OS is a non-cardiac, non-physiological cell line, this model has high fidelity for the core biochemical/assembly mechanism but cannot recapitulate the cardiomyopathy or organismal lethality phenotype — an important model_scale distinction (cellular/molecular readout only; no tissue- or organism-level readout) if curated into a modeled_mechanisms link.
• Patient-derived primary cells: Dermal fibroblasts (both families) and skeletal muscle biopsy tissue (second family) served as primary, disease-relevant (non-heterologous) models, directly showing isolated CIV deficiency and assembly-intermediate accumulation — these are patient material rather than "model organisms" per se but are the most disease-relevant functional evidence available.
• No zebrafish, Drosophila, or C. elegans COA5/Pet191-ortholog disease model was identified in this search pass, despite orthologs likely existing (COA5 is described elsewhere as having stringent mouse/zebrafish orthology per one GeneCards-derived summary) — flag as an unexploited/unreported model-organism gap rather than an established negative finding.

Summary of Notable Gaps for KB Curation

1. Age-at-death discrepancy (8–10 days vs. "3 months" from different secondary abstractions of PMID:21457908) — must be resolved against the primary paper.
2. CNS/encephalopathy phenotype is implied by the disease-class name but not directly documented in the sources retrieved here — verify in the primary text before curating a distinct CNS pathophysiology node.
3. gnomAD/ClinVar-level variant frequency and classification for c.157G>C were not independently pulled and should be confirmed directly.
4. Exact HGNC ID, GO molecular-function terms, and UniProt subcellular-localization detail for COA5 should be verified via OAK/UniProt lookup rather than taken from this search pass.
5. Mouse Coa5-null phenotype detail (viability, whether embryonic lethal) should be pulled directly from MGI's allele-specific phenotype pages.
6. No treatment, prevention, or model-organism-disease-recapitulation content beyond general extrapolation currently has direct COA5-specific citation support — this scarcity is itself the most important characteristic of this ultra-rare entry (two published families total) and should be represented honestly in the KB rather than padded with generic mitochondrial-disease boilerplate presented as disease-specific evidence.

Primary Sources / Citations

• Huigsloot M, et al. "A mutation in C2orf64 causes impaired cytochrome c oxidase assembly and mitochondrial cardiomyopathy." Am J Hum Genet. 2011;88(4):488–493. PMID:21457908
• COA5 has an essential role in the early stage of mitochondrial complex IV assembly — Life Science Alliance 2025 (preprint: medRxiv 2024.08.27.24312374). PMID:39779219
• OMIM #616500 — Mitochondrial Complex IV Deficiency, Nuclear Type 9
• OMIM *613920 — COA5
• Orphanet ORPHA:1561 — Fatal infantile cytochrome C oxidase deficiency
• NCBI Gene 493753 — COA5
• GTR Test 586086 — CEMCOX3/COA5 sequence analysis
• MGI:1923428 — Coa5 mouse gene detail
• NORD/MONDO disease abstraction

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• MONDO:0014667 (1 mention) - the report calls it "corresponds to MC4DN9"; MONDO calls it cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 3

Unresolved terms

These identifiers do not exist in an ontology that resolved other terms from the same prefix, so they were most likely invented:

• HP:0005633 (1 mention) - HP does not contain this term

Terms named inconsistently

The report gives these identifiers more than one name of its own:

• MGI:1923428 - called "Coa5", "Mouse:* Coa5", "Coa5 mouse gene detail"

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA, MGI.